Pacific Biosciences of California (PACB) PT Raised to $13 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Price: $2.62 +2.75%
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Cantor Fitzgerald analyst Ross Osborn raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $13.00 (from $12.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Pacific Biosciences of California (PACB) PT Raised to $3 at Piper Sandler
- Pacific Biosciences of California (PACB) PT Raised to $2 at Barclays
- Novo Nordisk (NVO) PT Raised to $44 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
